Nidan Labs & Healthcare
Nidan Laboratories & Healthcare Ltd
- P/E
- 4.41
Key Fundamentals
SMEHealthcare ServicesHealthcarePrice-based figures as of · TTM
- ROCE
- 5.99%
- Debt to Equity
- 0.16
- EPS (TTM)
- ₹2.90
- Book Value
- ₹50.14
- Market Cap
- —
- P/E (TTM)
- 4.41
- P/B
- 0.26
- ROE
- 2.58%
- Dividend Yield
- 0.00%
- EBITDA
- ₹6.70 Cr
- 52W High
- ₹24.90
- 52W Low
- ₹11.50
- Day Range
- ₹12.80 – ₹12.90
- Volume
- 2,000
Peer Comparison
Healthcare › Healthcare Services › Healthcare Service Provider
| ₹2,029.40 | 62.75 | ₹32,036 Cr | 13.58 | 0.26% | 22.30% | 28.00% | ₹2,891 Cr | ₹545 Cr | |
| ₹1,424.60 | 78.15 | ₹14,588 Cr | 15.33 | 0.14% | 18.30% | 20.50% | ₹857 Cr | ₹187 Cr | |
| ₹581.25 | 59.74 | ₹11,437 Cr | 8.03 | 0.88% | 13.60% | 17.80% | ₹1,710 Cr | ₹203 Cr | |
| ₹495.50 | 44.72 | ₹7,723 Cr | 14.25 | 2.90% | 28.40% | 35.40% | ₹876 Cr | ₹176 Cr | |
| ₹622.35 | 148.53 | ₹5,903 Cr | 5.61 | 0.00% | 8.83% | 15.30% | ₹1,053 Cr | ₹85 Cr | |
| ₹333.05 | 48.41 | ₹1,717 Cr | 7.08 | 0.15% | 14.20% | 17.30% | ₹325 Cr | ₹35 Cr | |
| ₹483.05 | 15.84 | ₹1,571 Cr | 1.51 | 0.41% | 10.90% | 12.70% | ₹726 Cr | ₹98 Cr | |
| Nidan Labs & Healthcare (this company) | ₹12.80 | 4.41 | ₹18 Cr | 0.26 | 0.00% | 2.58% | 5.99% | ₹24 Cr | ₹3 Cr |
| Median 8 companies | ₹538.38 | 54.08 | ₹6,813 Cr | 7.56 | 0.21% | 13.90% | 17.55% | ₹867 Cr | ₹137 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 59
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 81
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 43
- Weak
- Sales & profit trajectory 9% weight
- Financial Health
- 47
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 38
- Weak
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Stock is trading at 0.25 times its book value
- Company's working capital requirements have reduced from 87.8 days to 33.6 days
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 4.62% over past five years.
- Company has a low return on equity of 1.81% over last 3 years.
- Promoter holding has decreased over last 3 years: -5.75%
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 11 | 7 | 1 |
| Oscillators | Bearish | 2 | 7 | 0 |
| Moving Averages | Strong Bearish | 9 | 0 | 1 |
Oscillators
Bearish
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 47.19
- Neutral
- MACD (12,26,9)
- −0.14
- Bearish
- SMA (50)
- 13.29
- Bearish
- SMA (200)
- 14.92
- Bearish
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 5Y | +4.62% |
|---|---|
| 3Y | +1.71% |
| 1Y | +4.12% |
Net profit
| 5Y | −8.07% |
|---|---|
| 3Y | −24.72% |
| 1Y | −23.74% |
Operating cash flow
| 5Y | −17.43% |
|---|---|
| 3Y | −46.60% |
| 1Y | −29.24% |
Operating margin· change in pp
| 5Y | −24.67 pp |
|---|---|
| 3Y | −9.07 pp |
| 1Y | −1.68 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2019 | ₹20.07 Cr |
|---|---|
| Mar 2020 | ₹21.41 Cr |
| Mar 2021 | ₹20.38 Cr |
| Mar 2022 | ₹29.66 Cr |
| Mar 2023 | ₹24.27 Cr |
| Mar 2024 | ₹24.18 Cr |
| Mar 2025 | ₹24.53 Cr |
| Mar 2026 | ₹25.54 Cr |
Net profit by year
| Mar 2019 | ₹0.22 Cr |
|---|---|
| Mar 2020 | ₹0.71 Cr |
| Mar 2021 | ₹2.30 Cr |
| Mar 2022 | ₹2.66 Cr |
| Mar 2023 | ₹3.54 Cr |
| Mar 2024 | −₹3.23 Cr |
| Mar 2025 | ₹1.98 Cr |
| Mar 2026 | ₹1.51 Cr |
Half-yearly Results
₹ Cr| Particulars | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.14 | 14.09 | 10.18 | 11.82 | 12.35 | 10.53 | 13.99 | 13.12 | 12.42 |
| Expenses | 9.52 | 8.93 | 8.54 | 8.48 | 9.24 | 7.93 | 11.53 | 10.58 | 10.12 |
| Operating Profit | 3.62 | 5.16 | 1.64 | 3.34 | 3.11 | 2.6 | 2.46 | 2.54 | 2.3 |
| OPM % | 27.55% | 36.62% | 16.11% | 28.26% | 25.18% | 24.69% | 17.58% | 19.36% | 18.52% |
| Other Income | 0.39 | 0.33 | 3 | 1.52 | −5.29 | 1.03 | 1.22 | 1.17 | 0.29 |
| Interest | 0.95 | 1.03 | 1.19 | 0.98 | 1.2 | 0.88 | 1.26 | 0.88 | 1.07 |
| Depreciation | 0.87 | 1.44 | 1.66 | 1.28 | 1.59 | 1.34 | 1.07 | 0.92 | 0.98 |
| PBT | 2.19 | 3.02 | 1.79 | 2.6 | −4.97 | 1.41 | 1.35 | 1.91 | 0.54 |
| Tax % | 61.19% | 23.51% | 31.28% | 26.15% | 3.62% | 21.99% | 34.81% | 24.61% | 87.04% |
| Net Profit | 0.86 | 2.32 | 1.22 | 1.92 | −5.15 | 1.1 | 0.88 | 1.43 | 0.07 |
| EPS (₹) | 0.62 | 1.67 | 0.88 | 1.38 | −3.71 | 0.79 | 0.63 | 1.03 | 0.05 |
Profit & Loss
₹ Cr| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 20.07 | 21.41 | 20.38 | 29.66 | 24.27 | 24.18 | 24.53 | 25.54 |
| Expenses | 12.23 | 13.78 | 11.49 | 20.25 | 17.47 | 17.74 | 19.47 | 20.7 |
| Operating Profit | 7.84 | 7.63 | 8.89 | 9.41 | 6.8 | 6.44 | 5.06 | 4.84 |
| OPM % | 39.06% | 35.64% | 43.62% | 31.73% | 28.02% | 26.63% | 20.63% | 18.95% |
| Other Income | 0.37 | 0.01 | 1.06 | 0.4 | 3.33 | −3.76 | 2.25 | 1.46 |
| Interest | 4.75 | 3.74 | 3.46 | 2.66 | 2.22 | 2.18 | 2.14 | 1.96 |
| Depreciation | 3.24 | 3.19 | 3.18 | 2.63 | 3.1 | 2.87 | 2.41 | 1.9 |
| PBT | 0.22 | 0.71 | 3.31 | 4.52 | 4.81 | −2.37 | 2.76 | 2.44 |
| Tax % | 0% | 0% | 30.21% | 41.15% | 26.4% | 36.29% | 28.26% | 38.11% |
| Net Profit | 0.22 | 0.71 | 2.3 | 2.66 | 3.54 | −3.23 | 1.98 | 1.51 |
| EPS (₹) | 0.22 | 0.72 | 2.32 | 1.91 | 2.55 | −2.32 | 1.42 | 1.09 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9.9 | 9.9 | 9.9 | 13.9 | 13.9 | 13.9 | 13.9 | 13.9 |
| Reserves | 0.41 | 1.13 | 3.43 | 52 | 55.54 | 52.31 | 54.28 | 55.79 |
| Borrowings | 32.16 | 34.35 | 38.04 | 19.29 | 10.93 | 12.44 | 11.11 | 11.17 |
| Other Liabilities | 0.58 | −0.17 | 2.37 | 3.29 | 4.03 | 3.9 | 3.65 | 3.14 |
| Total Liabilities | 43.05 | 45.21 | 53.74 | 88.48 | 84.4 | 82.55 | 82.94 | 84 |
| Fixed Assets | 23.28 | 20.1 | 19.92 | 20.46 | 21.39 | 17.95 | 16.33 | 14.91 |
| CWIP | 0 | 0 | 0.23 | 3.81 | 0 | 0.04 | 0.15 | 0.15 |
| Investments | 0.53 | 0.53 | 0.27 | 0 | 0 | 0 | 20 | 20 |
| Other Assets | 19.24 | 24.58 | 33.32 | 64.21 | 63.01 | 64.56 | 46.46 | 48.94 |
| Total Assets | 43.05 | 45.21 | 53.74 | 88.48 | 84.4 | 82.55 | 82.94 | 84 |
Cash Flow
₹ Cr| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | 8.95 | 4.62 | 4.35 | 7.83 | 10.97 | 5.52 | 2.36 | 1.67 |
| Investing | 1 | −0.01 | −3.22 | −35.74 | −0.29 | −10.6 | −0.21 | 0.06 |
| Financing | −5.81 | −1.56 | −1.22 | 28.72 | −10.37 | −0.49 | −3.1 | −1.63 |
| Net Cash Flow | 4.14 | 3.05 | −0.1 | 0.8 | 0.32 | −5.57 | −0.95 | 0.1 |
| Free Cash Flow | 9.95 | 4.61 | 1.13 | 1.36 | 11.02 | 4.88 | 1.49 | 1.19 |
| CFO/OP | 114 | 61 | 49 | 96 | 162 | 129 | 78 | 55 |
Ratios
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 102 | 92.57 | 97.25 | 65.96 | 90.69 | 7.85 | 18.9 | 31.73 |
| Inventory Days | 16.98 | 12.88 | 18.17 | 25.99 | — | — | — | — |
| Days Payable | 117 | — | 213 | 136 | — | — | — | — |
| Cash Conversion Cycle | 2.29 | — | −97.64 | −43.89 | 90.69 | 7.85 | 18.9 | 31.73 |
| Working Capital Days | 256 | 292 | −189 | 54.52 | 43.46 | 243 | −13.39 | 33.58 |
| ROCE % | — | 10.13% | 13.99% | 10.09% | 8.17% | 7.95% | 6.17% | 5.99% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Nidan Labs & Healthcare insights
56 extracted metrics across FY19–FY26.
Documents
- 23 Apr 2026
- 17 Feb 2025
- 28 Dec 2023
- 20 Dec 2023
- 4 Oct 2022
- 28 Sep 2026
- 28 Sep 2026
- 25 Sep 2026
- 3 Sep 2026
Frequently Asked Questions about Nidan Labs & Healthcare
What does Nidan Laboratories & Healthcare Ltd do?
Where is Nidan Laboratories & Healthcare Ltd (NIDAN) listed?
Which sector does Nidan Laboratories & Healthcare Ltd belong to?
What is the PE ratio of Nidan Laboratories & Healthcare Ltd?
What is the 52-week high and low of Nidan Laboratories & Healthcare Ltd?
What is the Return on Equity (ROE) of Nidan Laboratories & Healthcare Ltd?
Company Information
Incorporated in 2000, Nidan Laboratories & Healthcare Ltd is in the business of providing various Healthcare and Diagnostics Services
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NIDAN.md for Nidan Laboratories & Healthcare Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.